Eur Rev Med Pharmacol Sci 2024; 28 (5): 2084-2094
DOI: 10.26355/eurrev_202403_35621

A 3.5-year clinical experience with perampanel for refractory epilepsy

T. Bin Teni, N.A. Almutairi, S. Abuhaimed, S. Alaskar, G. Alkhamis, B.A. Alsfouk, M.R. Almarzouqi, S. Alageel, A. Alsemari

Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia


OBJECTIVE: This study aimed to evaluate the efficacy and tolerability of perampanel, which was used in a cohort of patients with refractory epilepsy for up to 3.5 years in a real-world setting in Saudi Arabia.

PATIENTS AND METHODS: Data from the medical records of patients treated with perampanel between March 13th, 2017, and September 6th, 2020, at neurology clinics at King Faisal Specialist Hospital and Research Centre (KFSHRC), Riyadh and Jeddah, Saudi Arabia, was collected. The Liverpool Adverse Events Profile (LAEP) scale was also used to measure the adverse effects of perampanel.

RESULTS: Of the 75 included patients, 66.7% responded to perampanel at the last follow-up, including 22.7% seizure-free for at least the last six months, and 44% of patients responded with a ≥ 50% reduction in seizure frequency from baseline. The overall incidence of adverse effects that led to perampanel discontinuation was 13.3%; the most common adverse effect was aggressive behavior followed by sedation. Pre-existing psychiatric comorbidity was significantly associated with the incidence of psychiatric and behavioral adverse effects on perampanel (p = 0.0206). The mean score of LEAP was 40. The most frequently rated adverse effects in LEAP were “feelings of anger and aggression to others”, “nervousness and/or agitation” and “sleepiness”. The efficacy and tolerability of perampanel were dose-dependent. Dose 6 mg/day was the most frequently used dose that was taken by about one-third of patients at their last visit.

CONCLUSIONS: Perampanel was effective as an adjunctive treatment for intractable seizures, with a responder rate of 66.7%. The long-term tolerability of perampanel was generally good. Aggressive behavior was the most common reason for perampanel discontinuation. Patients should be counseled and monitored for these adverse effects, particularly those with a history of previous psychiatric and behavioral problems.

Free PDF Download

To cite this article

T. Bin Teni, N.A. Almutairi, S. Abuhaimed, S. Alaskar, G. Alkhamis, B.A. Alsfouk, M.R. Almarzouqi, S. Alageel, A. Alsemari
A 3.5-year clinical experience with perampanel for refractory epilepsy

Eur Rev Med Pharmacol Sci
Year: 2024
Vol. 28 - N. 5
Pages: 2084-2094
DOI: 10.26355/eurrev_202403_35621